Biodistribution of Boron Sulfhydryl (BSH) in Humans: A Quality Control of Analytical Methods*

Stragliotto, Giuseppe; Zbinden, Pascal; Pettersson, Orn-Anong; Fankhauser, Heinz

doi:10.1007/978-1-4615-3384-9_120

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, boron has poor tumour to blood ratios, poor solubility in aqueous or biological media, and lacks tumour specificity [26][27][28][29][30][31][32][33][34][35][36][37][38] . In recent work, [39] the two radionuclides combined were considered for treatment.…”

Section: Introductionmentioning

confidence: 99%

Gadolinium concentration analysis in brain phantom by X-ray fluorescence

Almalki

Majid

Butler

et al. 2010

Australas Phys Eng Sci Med

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Gadolinium concentration analysis in brain phantom by X-ray fluorescence

Almalki

Majid

Butler

et al. 2010

Australas Phys Eng Sci Med

View full text Add to dashboard Cite

Borocaptate Sodium (BSH) Pharmacokinetics in Glioma Patients

Fankhauser

Stragliotto

Zbinden

1992

Boron Neutron Capture Therapy

View full text Add to dashboard Cite

Biodistribution of Boron Sulfhydryl for Boron Neutron Capture Therapy in Patients with Intracranial Tumors

Stragliotto

Fankhauser

1995

Neurosurgery

View full text Add to dashboard Cite

The biodistribution of boron sulfhydryl (BSH) was evaluated for boron neutron capture therapy of brain tumors. A selective boron delivery to the neoplasm is a prerequisite for successful therapy. The uptake of BSH after intravenous administration was analyzed in neoplastic and normal tissues in 61 patients undergoing craniotomies for intracranial tumors. The patients received 10 to 100 mg of BSH/kg (5-50 mg of 10B/kg) body weight, 2 to 72 hours before surgery. The tumor boron concentrations ranged from 0.2 ppm (micrograms/g) in a low-grade glioma to 19.5 ppm in a high-grade glioma. The tumor to blood boron ratio rose above 1 in 15 of 24 high-grade intracerebral tumors, 18 h or more after BSH infusion. The boron concentration in high-grade tumors was heterogeneous. Low-grade intracerebral tumors showed a low boron concentration with a tumor to blood ratio below 1. Extracerebral tumors, mainly meningiomas, showed boron concentrations comparable with high-grade tumors, with a tumor to blood ratio above 1 in 10 of 17 patients. The boron concentrations in skin and muscle compared roughly with the blood values. Boron did not enter normal brain in any significant amount. In high-grade tumors, tumor to brain ratios were above 2. Low boron concentrations in normal brain make BSH safe for a Phase I normal tissue tolerance study. Computed tomographic contrast enhancement was evaluated to tumor boron uptake for 30 patients. Tumor enhancement on computed tomography does not permit the prediction of individual tumor boron concentrations; however, the absence of a contrast enhancement was always associated with low boron uptake.

show abstract

Biodistribution of Boron Sulfhydryl (BSH) in Humans: A Quality Control of Analytical Methods*

Cited by 4 publications

References 0 publications

Gadolinium concentration analysis in brain phantom by X-ray fluorescence

Gadolinium concentration analysis in brain phantom by X-ray fluorescence

Borocaptate Sodium (BSH) Pharmacokinetics in Glioma Patients

Biodistribution of Boron Sulfhydryl for Boron Neutron Capture Therapy in Patients with Intracranial Tumors

Contact Info

Product

Resources

About